ProteoGenix, Inc.

ProteoGenix, Inc. (ProteoGenix) is a provider of diagnostic testing products for the maternal-fetal health community. It was founded in 2002 and the investors of the company are New Leaf Venture Partners, TPG Biotech, Burrill & Company, and Kaiser Permanente Ventures. It principally focuses on conditions related to pregnancy and neonatal management by providing diagnostic tools that improve laboratory testing results to the maternal/fetal/neonatal health care community. The company utilizes nucleic acid-based molecular technologies and proteomic biomarkers in the development and commercialization of effective, minimally invasive diagnostics that allow comprehensive identification and management of intraamniotic infection, neonatal sepsis, preterm birth and other significant complications of pregnancy and the neonate. It specializes in offering intraamniotic infection (IAI) test which is a major contributor to preterm birth (PTB). ProteoGenix has a research and clinical office in Beaverton, Oregon. The company is headquartered in Costa Mesa, the US.

Street: 
3545 Howard Way
City: 
Costa Mesa
Postcode: 
92626
Federal State : 
United States
WebSite: 
www.proteogenix.com

Company Index Score

Current Index Score Historical Index Score
  • ProteoGenix, Inc. currently scores 50 % in the index.
  • ProteoGenix, Inc. is currently ranked equal 15 out of a total of 35419 included in the NS Company Index. This is the top 0.042 % of all companies.
  • ProteoGenix, Inc. is currently ranked 3 out of 8430 companies. This is in the top 0.036 % percent of Healthcare companies ranked in the index.
  • User perception of the company stands at 0 % percent. This differs 50 % percent over the score attributed to the company by other scoring factors.

Latest tweets